Navigation Links
Top Hepatitis C Treatments Equally Effective
Date:7/22/2009

Landmark assessment also finds treating early helps prevent liver failure

WEDNESDAY, July 22 (HealthDay News) -- A landmark hepatitis C virus study shows that the top two treatment options are equally effective and safe.

The long-awaited study, thought to be the largest of its kind, is important for the 180 million people worldwide -- 4 million in the United States -- who are infected with hepatitis C virus and at risk for liver scarring, organ failure and death.

Hepatitis C is America's leading cause of liver failure, liver cancer and liver transplantation. The disease is transmitted by contact with blood through sexual activities, drug use or personal care items.

The study of 3,070 adults at Johns Hopkins and 118 other U.S. medical centers showed that treating patients with either of the two standard antiviral therapies is safe and helps prevent liver damage.

The report appears online July 22 in the New England Journal of Medicine.

The drug therapies -- peginterferon alfa-2b plus ribavirin, or peginterferon alfa-2a plus ribavirin -- worked in 39.8 percent and 40.9 percent of patients, respectively. Commonly observed side effects included anemia, fatigue, headache, nausea, insomnia and depression.

The equality of the only two U.S. Food and Drug Administration-approved drug-treatment regimens for suppressing the virus surprised the researchers, according to a news release from Johns Hopkins.

"When considering treatments for hepatitis C infection, patients and their doctors now have solid evidence that they can weigh both antiviral therapies equally for effectiveness, safety and tolerability," Dr. Mark Sulkowski, medical director of the Johns Hopkins Center for Viral Hepatitis and the study's co-principal investigator, said in the news release.

While 10 percent to 13 percent of the study's participants quit the treatment because of side effects, Sulkowski said that was "within expectations for this type of therapy."

The researchers also found that the sooner patients get into treatment, the better.

"Treatment success is highly dependent on starting before liver cirrhosis has already set in, which can take from a year to decades," Sulkowski noted in the news release.

Evidence from the study also will help doctors learn more quickly whether the patient is responding to the drug therapy. This will allow patients to avoid side effects and the expense of taking unnecessary drugs.

The study was funded by the Schering-Plough Corp., the maker and provider of the study drugs ribavirin and peginterferon alfa-b.

More information

The U.S. Centers for Disease Control and Prevention has more information on hepatitis.



-- Dennis Thompson



SOURCE: Johns Hopkins University, news release, July 22, 2009


'/>"/>
Copyright©2009 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Mass. General-based research center will investigate why immune system fails to control hepatitis C
2. New Report Just Published: World Hepatitis C Virus And Therapeutics Market Report
3. Pharmasset Nominates PSI-938 as a New Nucleotide Analog Inhibitor of Hepatitis C for Preclinical Development
4. JNCI news brief: Hepatitis B virus mutations may predict risk of liver cancer
5. Hepatitis C Virus Market Will Expand Dramatically From $2 Billion in 2008 to Nearly $7.7 Billion in 2013
6. Good news for some hard-to-treat hepatitis C patients
7. Aethlon Medical Releases Shareholder Letter to Discuss the Treatment of Hepatitis-C Virus (HCV)
8. Pharmasset Initiates Phase 1b Multiple Ascending Dose Clinical Trial of PSI-7851 in Chronic Hepatitis C Patients
9. NEJM study points to new era in hepatitis C treatment
10. Resource for Those Living with Hepatitis C Announces Website Redesign
11. AUDIO from Medialink, Bayer Healthcare and Onyx Pharmaceuticals: Facts About Hepatitis
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Top Hepatitis C Treatments Equally Effective 
(Date:12/2/2016)... Miami, FL (PRWEB) , ... December 02, 2016 ... ... over 5,100 hot meals to needy individuals and families from eight different sites ... Florida on Thanksgiving Day. Over 1,000 volunteers worked very hard on Thanksgiving morning ...
(Date:12/2/2016)... (PRWEB) , ... December 02, 2016 , ... ‘Tis the ... winners of $1,000 each from the National Family Partnership and the Drug Enforcement Administration ... who decorated their homes and the 10 winning schools who decorated their campuses with ...
(Date:11/30/2016)... ... ... "I hate when the mixture of saliva and toothpaste runs down my toothbrush ... N.J. "I thought that there had to be a way to prevent this mess, ... to prevent saliva and toothpaste from running down the brush handle onto the hand ...
(Date:11/30/2016)... CA (PRWEB) , ... November 30, 2016 , ... ... disorder and mental health treatment has announced the opening of a new residential ... treatment for girls with mental health issues such as severe anxiety, depression, bi-polar ...
(Date:11/30/2016)... ... November 30, 2016 , ... The ... community that the FDA Binding Guidance goes into effect next month. Sponsors whose ... in the FDA Data Standards Catalog. The current FDA Data Standards Catalog specifies ...
Breaking Medicine News(10 mins):
(Date:12/2/2016)... -- Allergan plc (NYSE: AGN ), a leading ... announced Accelerated Share Repurchase (ASR) Program. Logo - ... , ... announced, the Company entered into a variable tenor ASR arrangement ... $10 billion of its ordinary shares. Approximately 40.5 million shares ...
(Date:11/30/2016)... , Nov 30, 2016 ... "US Market Overview for Neuromodulation, Neurovascular, Neurosurgical and Monitoring Devices ... ... The full report suite on the ... fluid external drainage systems, intracranial pressure monitoring devices, detachable coils, ...
(Date:11/30/2016)... Nov. 30, 2016 Varian Medical Systems (NYSE: ... America,s Most JUST Company in the Healthcare Equipment and ... magazine,s inaugural "JUST 100 List." The rankings are ... surveys ever conducted on attitudes towards corporate behavior, involving ... list ranks U.S companies against their peers within 32 ...
Breaking Medicine Technology: